Professional Documents
Culture Documents
Full download Translational Autoimmunity. Volume 5: Challenges for Autoimmune Diseases Nima Rezaei file pdf all chapter on 2024
Full download Translational Autoimmunity. Volume 5: Challenges for Autoimmune Diseases Nima Rezaei file pdf all chapter on 2024
Volume 5:
Challenges for Autoimmune Diseases
Nima Rezaei
Visit to download the full and correct content document:
https://ebookmass.com/product/translational-autoimmunity-volume-5-challenges-for-a
utoimmune-diseases-nima-rezaei/
More products digital (pdf, epub, mobi) instant
download maybe you interests ...
https://ebookmass.com/product/translational-autoimmunity-
volume-1-etiology-of-autoimmune-diseases-nima-rezaei/
https://ebookmass.com/product/translational-immunology-
volume-2-treatment-of-autoimmune-diseases-nima-rezaei/
https://ebookmass.com/product/translational-autoimmunity-
volume-3-autoimmune-disease-associated-with-different-clinical-
features-nima-rezaei/
https://ebookmass.com/product/nutrition-and-lifestyle-in-
neurological-autoimmune-diseases-multiple-sclerosis-1st-edition-
ronald-ross-watson/
Autoimmune Diseases in Domestic Animals Ian R. Tizard
https://ebookmass.com/product/autoimmune-diseases-in-domestic-
animals-ian-r-tizard/
https://ebookmass.com/product/antiphospholipid-syndrome-in-
systemic-autoimmune-diseases-2nd-edition-edition-ricard-cervera/
https://ebookmass.com/product/the-heart-in-systemic-autoimmune-
diseases-2nd-edition-edition-fabiola-atzeni/
https://ebookmass.com/product/the-digestive-involvement-in-
systemic-autoimmune-diseases-2nd-edition-edition-manuel-ramos-
casals/
https://ebookmass.com/product/autoimmune-neurology-1st-edition-
sean-j-pittock-and-angela-vincent-eds/
Translational Immunology
TRANSLATIONAL AUTOIMMUNITY,
VOL. 5
Translational Immunology
TRANSLATIONAL
AUTOIMMUNITY,
VOL. 5
Challenges for Autoimmune
Diseases
Edited by
Nima Rezaei
Professor, Department of Immunology, School of Medicine;
Head, Research Center for Immunodeficiencies, Children’s Medical Center,
Tehran University of Medical Sciences; Founding President,
Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA),
Universal Scientific Education and Research Network (USERN),
Tehran, Iran
Editorial Assistant
Niloufar Yazdanpanah
Managing Director, Network of Immunity in Infection,
Malignancy and Autoimmunity (NIIMA),
Universal Scientific Education and Research Network, (USERN); School of Medicine; and
Research Center for Immunodeficiencies, Children’s Medical Center,
Tehran University of Medical Sciences,
Tehran, Iran
Academic Press is an imprint of Elsevier
125 London Wall, London EC2Y 5AS, United Kingdom
525 B Street, Suite 1650, San Diego, CA 92101, United States
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom
Copyright © 2023 Elsevier Inc. All rights reserved.
No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical,
including photocopying, recording, or any information storage and retrieval system, without permission in writing from
the publisher. Details on how to seek permission, further information about the Publisher’s permissions policies and our
arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found
at our website: www.elsevier.com/permissions.
This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may
be noted herein).
Notices
Knowledge and best practice in this field are constantly changing. As new research and experience broaden our
understanding, changes in research methods, professional practices, or medical treatment may become necessary.
Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any
information, methods, compounds, or experiments described herein. In using such information or methods they should be
mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.
To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any
injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or
operation of any methods, products, instructions, or ideas contained in the material herein.
ISBN: 978-0-323-85389-7
This book would not have been possible without the continuous encouragement from my family.
I dedicate this book to my daughters, Ariana and Arnika, with the hope that we learn
enough from today to make a brighter future for the next generation.
Contents
1 Introduction 10 1 Introduction 37
2 Paul Ehrlich and the “horror autotoxicus” 10 2 Physiology of the skin 38
3 First evidence 11 3 Clinical characteristics of dermatitis; treatment
4 Autoimmunity in thyroid 11 and classification 39
5 Burnet and the prohibited clones 12 4 Molecular mimicry in atopic
6 Further evidence 12 dermatitis (AD) 40
7 Influence of HLA complex 13 5 Tools for the study and identification of
8 Vaccination and therapeutic approaches 14 autoantigens in atopic dermatitis 43
9 Criteria of definition and classification of 6 Particularities of type 2 immune response
autoimmune diseases 14 in atopic dermatitis 44
10 Conclusion 14 7 Conclusion 45
References 15 References 45
vii
viii Contents
Ethan G. Aguilar Division of Blood and Marrow Ángela Carrasco-Sayalero Immunology Depart-
Transplantation, Department of Pediatrics, ment, University Hospital Ramón y Cajal,
Masonic Cancer Center, University of Minne- Madrid, Spain
sota, Minneapolis, MN, United States Srikumar Chakravarthi School of Medical
Farah Asa’ad Department of Biomaterials, Sciences, Bharath Institute of Higher Educa-
Institute of Clinical Sciences, The Sahlgrenska tion and Research (BIHER), Chennai, India;
Academy, University of Gothenburg, Göteborg, Department of Pathology, Faculty of Medicine,
Sweden Bioscience and Nursing, MAHSA University,
Kiandokht Bashiri Center of Excellence for Jenjarom, Selangor, Malaysia
Gastrointestinal Inflammation and Immunity Mingyi Chen Department of Pathology, UT
Research; Division of Gastroenterology and Southwestern Medical Center, Dallas, TX,
Hepatology, University of Alberta, Edmonton, United States
AB, Canada Enrico Crivellato Department of Medicine,
Rasheedunnisa Begum Department of Biochem- Section of Human Anatomy, University of
istry, Faculty of Science, The Maharaja Sayajirao Udine, Udine, Italy
University of Baroda, Vadodara, Gujarat, India Biagio Didona Department of Dermatology,
Marcel W. Bekkenk Department of Dermatol- IDI-IRCCS, Rome, Italy
ogy, Amsterdam UMC, University of Amster- Dario Didona Department of Dermatology and
dam, the Netherlands Allergology, Philipps University, Marburg,
Ankit H. Bharti Dr. Ankit’s Dermatopathology Germany
Research Centre, Vyara, Gujarat, India Sulagna Dutta Department of Oral Biology
Bruce R. Blazar Division of Blood and Marrow and Biomedical Sciences, Faculty of Den-
Transplantation, Department of Pediatrics, tistry, MAHSA University, Jenjarom, Selangor,
Masonic Cancer Center, University of Minne- Malaysia; School of Medical Sciences, Bharath
sota, Minneapolis, MN, United States Institute of Higher Education and Research
Siebe G. Blok Department of Dermatology, (BIHER), Chennai, India
Amsterdam UMC, University of Amsterdam, Mitesh Dwivedi C. G. Bhakta Institute of Bio-
the Netherlands technology, Faculty of Science, Uka Tarsadia
Sara Bolivar-Wagers Division of Blood and University, Surat, Gujarat, India
Marrow Transplantation, Department of Raquel Echavarria CONACyT-Western Biomed-
Pediatrics, Masonic Cancer Center, University ical Research Center, Mexican Institute of Social
of Minnesota, Minneapolis, MN, United States Security, Guadalajara, Jalisco, Mexico
Emiro Buendía Faculty of Medicine, University Yannick S. Elshot Department of Dermatol-
of Cartagena; Department of Internal Medicine, ogy, Amsterdam UMC, University of Amster-
Serena del Mar Hospital Center, Cartagena, dam; Department of Dermatology, The
Colombia Netherlands Cancer Institute, Amsterdam,
Raffaele Dante Caposiena Caro Department of The Netherlands
Dermatology; Department of Systems Medicine, Luca Fania Department of Dermatology, IDI-
University of Rome Tor Vergata, Rome, Italy IRCCS, Rome, Italy
xi
xii Contributors
xv
xvi Preface
This book begins with an introduction autoimmune diseases. Chapters 10–15 take
to the challenges in different aspects of a focused view on the challenges that exist
autoimmune diseases in Chapter 1. Chapter 2 in autoimmune diseases targeting different
focuses on a part of the history of autoim- tissues. Finally, Chapters 16–18 discuss some
mune diseases and the challenges in the iden- important challenges in the treatment of au-
tification of these conditions. Chapters 3 and toimmune diseases.
4 dive deep into the challenges in the appli- The Translational Immunology book series
cation of some of the diagnostic tools of auto- is the outcome of the invaluable contribution
immune diseases. In addition, Chapters 5 and of scientists and clinicians from well-known
6 are devoted to challenges in the research universities/institutes worldwide. I hereby
path in the field of cutaneous autoimmune appreciate and acknowledge the expertise
diseases, an important group of autoim- of all contributors for generously devoting
mune diseases. Chapter 7 emphasizes the their time and considerable effort in prepar-
possibility of autoimmunity following newly ing their respective chapters. I also express
emerged diseases, by discussing the pediat- my gratitude to Elsevier for providing me
ric inflammatory multisystem syndrome the opportunity to publish this book. Finally,
following COVID-19, which raised concerns I hope this translational book will be com-
for pediatric health since the start of the pan- prehensible, cogent, and of special value to
demic. In addition, some contributors to the researchers and clinicians who wish to ex-
pathophysiology of autoimmune diseases tend their knowledge in immunology.
are explored in Chapters 8 and 9, to highlight
the challenges in the pathophysiology of Nima Rezaei
Series editor biography
xvii
Acknowledgment
I express my gratitude to the editorial assistant of this book, Dr. Niloufar Yazdanpanah,
without whose contribution this book would not have been completed.
xix
Abbreviations
xxi
xxii Abbreviations
1
Introduction on challenges
for autoimmune diseases
Niloufar Yazdanpanaha,b,d and Nima Rezaeib,c,d,⁎
a
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran bResearch Center for
Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran,
Iran cDepartment of Immunology, School of Medicine, Tehran University of Medical Sciences,
Tehran, Iran dNetwork of Immunity in Infection, Malignancy and Autoimmunity (NIIMA),
Universal Scientific Education and Research Network (USERN), Tehran, Iran
⁎
Corresponding author
Abstract
Autoimmune diseases have remained a mysterious territory in medical sciences. Considering the unanswered
questions concerning the ethiopathogenesis of autoimmune diseases, many challenges remained to be tack-
led in this field. The prevention, diagnosis, treatment, and prognosis of autoimmune diseases are affected by
different factors; for instance, the specificity and sensitivity of most diagnostic tools as well as the therapeutic
agents do not meet the expectations, while there is no validated marker for disease prediction or prognosis.
Nevertheless, new fields of research including multiomics analysis, immunometabolism, genetic studies, and
precision medicine could be promising tools to address the existing challenges in autoimmune diseases.
Keywords
Autoimmune, Autoimmunity, Challenges, Pathophysiology, Diagnosis, Treatment, Prevention
1 Introduction
Autoimmune diseases are known as the consequence of the immune system’s misrecogni-
tion of self-antigens as harmful. About 5%–8% of the world population suffers from autoim-
mune diseases [1]; meanwhile, due to the need for a prolonged period of treatment, life-long
treatment in some cases, autoimmune diseases impart a remarkable burden to the healthcare
system and affect the countries’ socioeconomic status. Being studied for decades, many ques-
tions about autoimmune diseases remained to be addressed.
Translational Autoimmunity, Vol. 5 1 Copyright © 2023 Elsevier Inc. All rights reserved.
https://doi.org/10.1016/B978-0-323-85389-7.00014-4
1. Challenges in autoimmune diseases
2 Challenges in pathophysiology
2
Niloufar Yazdanpanah and Nima Rezaei
3 Challenges in diagnosis
While in most cases the diagnosis of autoimmune disease is established according to the
initial organ involvement and the medical specialty that the patient is referred to, the con-
currence of two or more autoimmune diseases in the same patient and at the same time is
reported in 0.4%–0.5% of the global population diagnosed with autoimmune diseases [4]. It
is commonly reported in multiple sclerosis (MS), autoimmune thyroiditis, rheumatoid arthri-
tis (RA), type 1 diabetes mellitus (T1DM), inflammatory bowel disease (IBD), and vitiligo.
Two definitions, multiple autoimmune syndromes (MAS) and overlap syndromes, are made
to classify these conditions. Addison’s syndrome was the first case that introduced as an
integration of different autoimmune conditions, namely adrenal insufficiency, vitiligo, and
pernicious anemia [5]. MAS is used for conditions previously defined as autoimmune poly-
glandular syndrome (APS) [6]. This definition consists of both complete MAS and incomplete
MAS, of which incomplete subtypes are more common. For instance, detection of autoanti-
bodies related to other autoimmune diseases in a patient with one established autoimmune
condition is classified as incomplete MAS [7]. Overlap syndromes are known as conditions,
occurring in an individual at the same time or different periods, fulfilling the classification
criteria of at minimum two autoimmune diseases; this condition is mainly established in con-
nective tissue diseases and liver diseases [8,9]. Identification of MAS and overlap syndromes
and diagnosis of these conditions in the clinic could play an integral role in disease man-
agement, treatment, and prognosis. In addition, in cases of overlap syndromes, perdition of
the forthcoming autoimmune complications in a patient with an established diagnosis of an
autoimmune disease could help to prevent the progression of other associated autoimmune
complications by starting the treatment at early stages.
Progression of autoimmune diseases to the complete phenotype of the disease can take
weeks to months. Within this period, the level of autoantibodies undergoes a wax and wane
process [10]. Hence, autoantibodies alone could not be counted as a diagnostic method due to
their altered levels during the disease. In line with this, identification of novel biomarkers for
autoimmune diseases has been an interesting area of research. On the other hand, there are
some ethical issues with conducting vast case–control and cohort studies. For instance, in case,
a participant that enters the study without any preexisting autoimmune diseases and during
3
1. Challenges in autoimmune diseases
the evaluation becomes positive for a marker that predicts a high risk of developing autoimmu-
nity, it is controversial whether it is ethical to induce anxiety and stress in a healthy participant
who may or may not develop the predicted disease. Application of genomics, proteomics, ri-
bonomics, and metabolomics research could be helpful in the recognition of new autoantigens,
autoantibodies, and biomarkers for autoimmune diseases [11]. Finding specific markers for au-
toimmune diseases potentially facilitates the diagnosis process since, currently, the diagnosis of
most autoimmune diseases is based on the exclusion of other medical conditions.
4 Challenges in treatment
Treatment of autoimmune diseases has been always faced different challenges. Currently,
widely available drugs for autoimmune diseases are nonspecific and associated with various
adverse effects. The treatment armamentarium of autoimmune diseases includes corticoste-
roids, immunomodulatory agents, and some limited cytotoxic drugs. However, extensive
research is ongoing to find novel specific therapeutic agents with limited adverse effects to
optimize the course of treatment. On the other hand, the associated complications of autoim-
munity, including malignancies and infections, challenge the treatment process. The role of
the patient in experiencing a successful course of treatment is undeniable. In the following
sections, we provide a comprehensive review of challenges concerning the treatment of au-
toimmune diseases.
4
Niloufar Yazdanpanah and Nima Rezaei
have been applied as adjuncts to DMARDs. B cells, cytokines, costimulatory molecules, and
B cell receptors are the targets of biological agents. Although this type of targeted therapy is
properly tolerated in patients, they are not included in the first-line treatment options, due to
the route of administration (intravenous, which is not preferred by most of the patients) and
the high expenses [15].
5
1. Challenges in autoimmune diseases
c ardiovascular diseases, gene therapy approaches have been proposed for the treatment of
autoimmune diseases as well [23]. There are several reports concerning the positive effect
of gene therapy in reducing the severity of symptoms in autoimmune animal models. For
instance, Kok et al. observed that a recombinant adeno-associated virus (rAAV) vector which
coded IL-10 considerably improve the salivary glands pathological markers in Sjogren’s syn-
drome model in nonobese diabetic (NOD) mice [24]. Furthermore, besides viral vectors, T
cells and B cells have represented great promises in carrying genes for immunomodulatory
purposes. As an example, Guichelaar et al. reported that transferring the IL-10 gene by adop-
tive autoantigen-specific CD4+ T cells transfer could be a potentially effective approach to
compensate for the altered T cell regulation in mice with chronic arthritis [25]. Drawing a con-
clusion upon this perspective, genetic studies to identify the responsible genes in the patho-
physiology of autoimmune diseases and observational studies for recognizing biomarkers
could lead to choosing a proper target for gene therapy in autoimmune diseases. Meanwhile,
the application of siRNA, miRNA, and mesenchymal stem cells could provide novel oppor-
tunities for the treatment of autoimmune diseases.
5 Challenges in prevention
6
Niloufar Yazdanpanah and Nima Rezaei
6 Conclusion
References
[1] L. Fugger, L.T. Jensen, J. Rossjohn, Challenges, progress, and prospects of developing therapies to treat autoim-
mune diseases, Cell 181 (1) (2020) 63–80.
[2] R. Bacchetta, F. Barzaghi, M.G. Roncarolo, From IPEX syndrome to FOXP3 mutation: a lesson on immune dys-
regulation, Ann. N. Y. Acad. Sci. 1417 (1) (2018) 5–22.
[3] K.L. Moser, J.A. Kelly, C.J. Lessard, J.B. Harley, Recent insights into the genetic basis of systemic lupus erythe-
matosus, Genes Immun. 10 (5) (2009) 373–379.
[4] R. Tozzoli, M.C. Sorrentino, N. Bizzaro, Detecting multiple autoantibodies to diagnose autoimmune co-
morbidity (multiple autoimmune syndromes and overlap syndromes): a challenge for the autoimmunologist,
Immunol. Res. 56 (2) (2013) 425–431.
[5] J.L. Graner, Addison, pernicious anemia and adrenal insufficiency, CMAJ 133 (9) (1985) 855–857. 80.
[6] C. Betterle, F. Presotto, Chapter 12: Autoimmune polyendocrine syndromes (APS) or multiple autoimmune
syndromes (MAS), in: S.E. Walker, L.J. Jara (Eds.), Handbook of Systemic Autoimmune Diseases, vol. 9,
Elsevier, 2008, pp. 135–148.
[7] A.P. Weetman, Non-thyroid autoantibodies in autoimmune thyroid disease, Best Pract. Res. Clin. Endocrinol.
Metab. 19 (1) (2005) 17–32.
[8] A.J. Czaja, The overlap syndromes of autoimmune hepatitis, Dig. Dis. Sci. 58 (2) (2013) 326–343.
[9] L. Iaccarino, M. Gatto, S. Bettio, F. Caso, M. Rampudda, M. Zen, et al., Overlap connective tissue disease syn-
dromes, Autoimmun. Rev. 12 (3) (2013) 363–373.
[10] Y. Yamasaki, S. Narain, H. Yoshida, L. Hernandez, T. Barker, P.C. Hahn, et al., Autoantibodies to RNA helicase
a: a new serologic marker of early lupus, Arthritis Rheum. 56 (2) (2007) 596–604.
[11] Y. Xiang, T. Kato, Use of proteomics in analysis of autoimmune diseases, Lupus 15 (7) (2006) 431–435.
[12] R. Li, X. Sun, X. Liu, Y. Yang, Z. Li, Chapter seven—Autoimmune diseases in China, in: C. Dong, Z. Jiang (Eds.),
Advances in Immunology, vol. 144, Academic Press, 2019, pp. 173–216.
[13] A.C. Cannella, J.R. O'Dell, Chapter 61—Traditional DMARDs: methotrexate, leflunomide, sulfasalazine, hy-
droxychloroquine, and combination therapies, in: G.S. Firestein, R.C. Budd, S.E. Gabriel, M.I. IB, J.R. O'Dell
(Eds.), Kelley and Firestein's Textbook of Rheumatology, tenth ed., Elsevier, 2017, pp. 958–982.e7.
[14] P. Spagnolo, E. Cocconcelli, Drug toxicity and interstitial lung disease, in: S.M. Janes (Ed.), Encyclopedia of
Respiratory Medicine, second ed., Academic Press, Oxford, 2022, pp. 358–367.
[15] Z. Rosman, Y. Shoenfeld, G. Zandman-Goddard, Biologic therapy for autoimmune diseases: an update, BMC
Med. 11 (1) (2013) 88.
[16] A.L. Franks, J.E. Slansky, Multiple associations between a broad spectrum of autoimmune diseases, chronic
inflammatory diseases and cancer, Anticancer Res 32 (4) (2012) 1119–1136.
[17] C. Criscitiello, V. Bagnardi, A. Esposito, L. Gelao, B. Santillo, G. Viale, et al., Impact of autoimmune diseases on
outcome of patients with early breast cancer, Oncotarget 7 (32) (2016) 51184–51192.
[18] K. Hemminki, X. Liu, J. Ji, J. Sundquist, K. Sundquist, Effect of autoimmune diseases on mortality and survival
in subsequent digestive tract cancers, Ann. Oncol. 23 (8) (2012) 2179–2184.
[19] L. Makowski, M. Chaib, J.C. Rathmell, Immunometabolism: from basic mechanisms to translation, Immunol.
Rev. 295 (1) (2020) 5–14.
[20] T. Daikeler, A. Tichelli, J. Passweg, Complications of autologous hematopoietic stem cell transplantation for
patients with autoimmune diseases, Pediatr. Res. 71 (2) (2012) 439–444.
7
1. Challenges in autoimmune diseases
[21] J.F. Swart, E.M. Delemarre, F. van Wijk, J.-J. Boelens, J. Kuball, J.M. van Laar, et al., Haematopoietic stem cell
transplantation for autoimmune diseases, Nat. Rev. Rheumatol. 13 (4) (2017) 244–256.
[22] S.A. Rosenberg, P. Aebersold, K. Cornetta, A. Kasid, R.A. Morgan, R. Moen, et al., Gene transfer into humans—
immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by ret-
roviral gene transduction, N. Engl. J. Med. 323 (9) (1990) 570–578.
[23] P.S.C. Leung, A. Dhirapong, P.-Y. Wu, M.-H. Tao, Gene therapy in autoimmune diseases: challenges and oppor-
tunities, Autoimmun. Rev. 9 (3) (2010) 170–174.
[24] M.R. Kok, S. Yamano, B.M. Lodde, J. Wang, R.I. Couwenhoven, S. Yakar, et al., Local adeno-associated
virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjögren's syn-
drome, Hum. Gene Ther. 14 (17) (2003) 1605–1618.
[25] T. Guichelaar, C.B. ten Brink, P.J. van Kooten, S.E. Berlo, C.P. Broeren, W. van Eden, et al., Autoantigen-specific
IL-10-transduced T cells suppress chronic arthritis by promoting the endogenous regulatory IL-10 response,
J. Immunol. 180 (3) (2008) 1373.
[26] L.R. Martin, S.L. Williams, K.B. Haskard, M.R. Dimatteo, The challenge of patient adherence, Ther. Clin. Risk
Manag. 1 (3) (2005) 189–199.
[27] J. Turner, B. Kelly, Emotional dimensions of chronic disease, West. J. Med. 172 (2) (2000) 124–128.
[28] D. Shepshelovich, Y. Shoenfeld, Prediction and prevention of autoimmune diseases: additional aspects of the
mosaic of autoimmunity, Lupus 15 (3) (2006) 183–190.
[29] N.R. Rose, Prediction and prevention of autoimmune disease in the 21st century: a review and preview, Am.
J. Epidemiol. 183 (5) (2016) 403–406.
8
C H A P T E R
2
From horror autotoxicus to
autoimmunity. An historical note
Domenico Ribattia,⁎ and Enrico Crivellatob
a
Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari
Medical School, Bari, Italy bDepartment of Medicine, Section of Human Anatomy, University of
Udine, Udine, Italy
⁎
Corresponding author
Abstract
At the beginning of the 20th century, the knowledge on autoimmunity was very limited. In 1899, Jules Bordet
demonstrated that autoantibodies specific for erythrocytes could cause their own destruction in conjunction
with serum complement. In 1904, Julius Donath and Karl Landsteiner reported the first observation of a true
autoimmune disease, paroxysmal cold hemoglobinuria, a complement-dependent hemolytic anemia. They
demonstrated the presence of a lytic substance in the blood of three patients with paroxysmal cold hemoglo-
binuria. An autoimmune disease can generally be defined as one in which an autoantibody or a sensitized
lymphocyte reacts with host tissue. The prevalence of autoimmune diseases is significantly increasing in the
world population. We now recognize more than 80 clinically distinct human diseases that result at least in part
from an autoimmune response. Autoimmune diseases generally result from the association of genetic suscep-
tibility and environmental triggers. Infectious agents have long been the most well-studied environmental
factors. Despite the diversity in natural history and presentation, autoimmune diseases share a number of
underlying mechanisms. More selective and less toxic immunosuppressive and immunomodulatory agents
are used to treat these disorders, and promising immune tolerance approaches are emerging.
Keywords
Autoimmunity, Horror autotoxicus, History of immunology
Translational Autoimmunity, Vol. 5 9 Copyright © 2023 Elsevier Inc. All rights reserved.
https://doi.org/10.1016/B978-0-323-85389-7.00006-5
Another random document with
no related content on Scribd:
julisti kuningas Limbilin maailman suurimmaksi kuninkaaksi, parhaan
armeijan päälliköksi ja mahtavan kuningaskunnan valtiaaksi.
Eräänä päivänä, kun maailma oli viileä ja ilma oli täynnä Afrikan
kevään hienoa tuoksua, Sanders oli matkalla pienten maakuntien
halki. Ne ovat niitä maita, jotka ovat kaukana suurilta joilta. Maita,
jotka ovat kansainvälisten rajojen halkomia tai ulottuvat jonnekin
erämaihin ja joihin kartoittaja on merkinnyt: »Englannin suojeluksen
alla».
Tyttö rypisti otsaansa hieman, otti hieman nenäänsä, sillä hän oli
viidentoista ikäinen nainen eikä millään muotoa toisenlainen kuin
maailman muut naiset. Tätä Sanders ei tietänyt, ja vaikka olisi
tietänytkin, tokkopa se olisi häntä paljoa auttanut.
Sanders palasi oman väkensä luo hiljoilleen. Hän viipyi yli viikon
Isisissä selvittelemässä erästä poppajuttua; Belembissä (Isisin
maassa) hän pysähtyi kolmeksi päiväksi selvittämään erästä
puujumalan tekemää murhaa. Hän jakoi oikeutta ja Abibu,
poliisikersantti, valikoi ja käytteli kankeimpia ruokojaan tuomitun
pieksämiseen, kun Ikelin päällikkö tuli paeten jokea myötävirtaa
kolmella kanootilla, ja Sanders, joka paikaltaan näki loputtoman joen,
arvasi, että oli sattunut selkkaus, ja tiesi, millainen selkkaus se oli.
— No, voi niin olla, myönsi vihastunut isä, — mutta olisihan ollut
hullua sanoa ensin liian pieni hinta.
Hän piti höyryä pikku laivassaan — hän oli valinnut ainoan paikan,
jossa joki koski Jitingin rajaa — ja odotti valmiina tekemään
häpeällisen, vaikka laillisen leikkauksen.
Sitten yksi ryhmä erkani joukosta ja tuli joen rannalla olevan puun
luo, johon oli kiinnitetty Englannin lippu.
— Sandi, sanoi hän, — kerran sinä tuotit minulle häpeän, sillä kun
minä tanssin sinulle, sinä nukuit.
— Sinulle, Daihili, sanoi Sanders yksikantaan, — minä en puhu
mitään; en keskustele naisten kanssa, sillä se ei ole tapa. Vielä
vähemmän minä puhun tanssivien tyttöjen kanssa. Minulla on asiaa
kuningas Limbilille.
— Pam! Pam!
Juttu oli alusta pitäen ollut toivoton. Sanders totesi sen jotenkin
filosofisesti, kun hän makasi pitkänään paljaalla maalla, sidottuna
kuin varis ja tuntien olonsa epämukavaksi. Kohta ensimmäisen
laukauksen pamahdettua Abibu oli saamiensa ohjeitten mukaan
kääntänyt laivan keulan myötävirtaan; tämä oli ainoa vähäinen
lohdutus, joka hänellä oli tässä tilanteessa.
»Ha-ha-ha-ha-a-aa!»
*****
— Mutta jos sinä jäät elämään, sanoi Sanders, — niin toiset suuret
kuninkaat sanovat: Saamme tehdä näitä julmuuksia, ja
suuruutemme tähden me saamme elää.
Hänen laivansa oli kiinnitetty joen rantaan. Tässä oli pieni lahti, ja
joen nopeat pyörteet olivat tässä muuttuneet tasaiseksi virraksi; siitä
huolimatta hän tarkasti köysien rannalla olevat kiinnikkeet, ennen
kuin astui »Zairen» kannelle johtavalle kapealle lankulle. Kannelle oli
pinottu puita valmiiksi huomenna alkavaa matkaa varten. Joka,
koneenkäyttäjä, oli asettanut uuden vesimittarin, niinkuin hän oli
käskenyt, ja koneet olivat puhdistetut. Sanders nyökkäsi
hyväksyvästi. Hän astui parin tai kolmen nukkuvan yli ja tuli rannalle.
— Taitaapa olla aika mennä sisään, mutisi hän ja katsoi kelloa. Se oli
yhdeksän. Hän seisoi hetken jyrkän rinteen harjalla ja katsoi joen yli.
Yö oli synkkä, mutta hän näki toisella rannalla olevan metsän
piirteet. Hän näki tähdikkään taivaan ja tähtien kalpean heijastuksen
vedessä. Sitten hän meni telttaansa ja pukeutui hiljalleen
yöpukuunsa. Hän nieli kaksi pilleriä, joi lasin vettä ja pisti päänsä
ulos teltan ovesta. — Ho, Sokani, hän sanoi puhuen murretta, —
anna lokalin soida!
Hän kävi nukkumaan.
Hän kuunteli.
— Valkea mies!
Kauniiden unien laakso! Siitä olisi tullut kaunis kirja, jos Mainward
olisi osannut kirjoittaa, mutta onnettomuudeksi hän ei osannut. Hän
saattoi allekirjoittaa papereita, hän saattoi kirjoittaa nimensä:
»Kolmen kuukauden kuluttua tästä päivästä maksakaa -». Hän osasi
myös kirjoittaa toisten nimiä; hän kirosi ja päivitteli sitä ajatellessaan.
— Puk-a-puk — kuulethan.
Sanders nyökkäsi.